Literature DB >> 12822577

Post transplant lymphoproliferative disorders following reduced intensity conditioning with in vivo T cell depletion.

K S Peggs, L Banerjee, K Thomson, S Mackinnon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12822577     DOI： 10.1038/sj.bmt.1703893

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  4 in total

Review 1.  Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited.

Authors:  Abhinav Deol; Lawrence G Lum
Journal:  Cancer Treat Rev       Date:  2010-04-09       Impact factor: 12.111

2.  WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.

Authors:  Eleanor M Tyler; Achim A Jungbluth; Richard J O'Reilly; Guenther Koehne
Journal:  Blood       Date:  2012-11-16       Impact factor: 22.113

3.  EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era.

Authors:  C P Fox; D Burns; A N Parker; K S Peggs; C M Harvey; S Natarajan; D I Marks; B Jackson; G Chakupurakal; M Dennis; Z Lim; G Cook; B Carpenter; A R Pettitt; S Mathew; L Connelly-Smith; J A L Yin; M Viskaduraki; R Chakraverty; K Orchard; B E Shaw; J L Byrne; C Brookes; C F Craddock; S Chaganti
Journal:  Bone Marrow Transplant       Date:  2013-11-11       Impact factor: 5.483

4.  Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.

Authors:  D M Burns; S Rana; E Martin; S Nagra; J Ward; H Osman; A I Bell; P Moss; N H Russell; C F Craddock; C P Fox; S Chaganti
Journal:  Bone Marrow Transplant       Date:  2016-02-22       Impact factor: 5.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.